SCHEMBL14923561

SCHEMBL14923561

C[C@H](N)[C@@H](C)Nc1nc(Cl)c(C#N)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KHK P50053 1/20 0.51
JAK3 P52333 5/20 0.35
JAK2 O60674 4/20 0.35
LIMK1 P53667 1/20 0.35
LIMK2 P53671 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CDK2 P24941 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MUSK O15146 1/20 0.33
NTRK1 P04629 1/20 0.33
LCK P06239 1/20 0.33
RET P07949 1/20 0.33
FGFR3 P22607 1/20 0.33
CCNE1 P24864 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3389612 1.00 KHK (0.51) KHKJAK3JAK2LIMK1LIMK2
SCHEMBL14909031 1.00 KHK (0.51) KHKJAK3JAK2LIMK1LIMK2
SCHEMBL14928506 0.89 KHK (0.50) KHKJAK3JAK2LIMK1LIMK2
SCHEMBL14928564 0.89 KHK (0.50) KHKJAK3JAK2LIMK1LIMK2
SCHEMBL16169054 0.85 KHK (0.48) KHKJAK3JAK2LIMK1LIMK2
SCHEMBL14928541 0.84 KHK (0.47) KHKJAK3JAK2LIMK1LIMK2
SCHEMBL14928398 0.84 KHK (0.46) KHKJAK3JAK2LIMK1LIMK2
SCHEMBL16169029 0.83 KHK (0.50) KHKJAK3JAK2LIMK1LIMK2
SCHEMBL16169053 0.83 KHK (0.44) KHKJAK3JAK2LIMK1LIMK2
SCHEMBL14909860 0.82 KHK (0.50) KHKJAK3JAK2LIMK1LIMK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK KHK 2008/4885JAK3 302/4885JAK2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.